ArticleScientific reports2026
An interpretable machine learning model using routine clinical data for early recurrence prediction in hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of early postoperative recurrence in hepatocellular carcinoma (HCC) remains challenging. We developed and validated an interpretable machine learning model to predict early recurrence after curative hepatectomy using routine clinical data. A cohort of 1,120 HCC patients from two centers (2014–2024) was split into training, hold-out test, and external validation sets. Nine predictors were selected via univariate Cox regression. The model integrated three machine learning algorithms to predict recurrence-free survival. In hold-out testing, it outperformed conventional staging in time-dependent area under the curve (0.772 vs. 0.637 at 4–24 months) and stratified patients into distinct low-, moderate-, and high-risk groups. Compared to high-risk patients, moderate-risk patients had significantly lower recurrence hazard (HR = 0.39; 95% CI: 0.24–0.64), and low-risk patients exhibited markedly reduced risk (HR = 0.10; 95% CI: 0.03–0.27). External validation confirmed robust risk stratification (log-rank test, p < 0.001). SHapley Additive exPlanations analysis identified tumor diameter as the top predictor, enabling transparent and personalized risk profiling. This model provides a non-invasive, cost-effective, and generalizable tool for predicting early HCC recurrence with enhanced interpretability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.